1. Home
  2. Publications
  3. Increased FOXJ1 protein expression is associated...

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.

Abstract:
BACKGROUND: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein expression assays by immunohistochemistry and validate their survival association in HGSC. METHODS: Two prognostic genes, FOXJ1 and GMNN, were selected based on high-quality antibodies, correlation with protein expression and variation in immunohistochemical scores in a preliminary cohort (n = 134 and n = 80, respectively). Six thousand four hundred and thirty-four (FOXJ1) and 5470 (GMNN) formalin-fixed, paraffin-embedded ovarian neoplasms (4634 and 4185 HGSC, respectively) represented on tissue microarrays from the Ovarian Tumor Tissue Analysis consortium underwent immunohistochemical staining and scoring, then univariate and multivariate survival analysis. RESULTS: Consistent with mRNA, FOXJ1 protein expression exhibited a linear, increasing association with improved overall survival in HGSC patients. Women with >50% expression had the most favourable outcomes (HR = 0.78, 95% CI 0.67-0.91, p 35% GMNN expression showed a trend for better outcomes, though this was not significant. CONCLUSION: We provide foundational evidence for the prognostic value of FOXJ1 in HGSC, validating the prior mRNA-based prognostic association by immunohistochemistry.
Authors:
A Weir, E-Y Kang, NS Meagher, GS Nelson, P Ghatage, C-H Lee, MJ Riggan, A Gentry-Maharaj, A Ryan, N Singh, M Widschwendter, J Alsop, MS Anglesio, MW Beckmann, J Berger, C Bisinotto, J Boros, AH Brand, JD Brenton, A Brooks-Wilson, ME Carney, JM Cunningham, KL Cushing-Haugen, C Cybulski, E Elishaev, R Erber, S Fereday, A Fischer, L Paz-Ares, J Gayarre, BC Gilks, M Grube, PR Harnett, HR Harris, A Hartmann, A Hein, J Hendley, BY Hernandez, S Heublein, Y Huang, T Huzarski, A Jakubowska, M Jimenez-Linan, CJ Kennedy, FKF Kommoss, JM Koziak, B Kraemer, ND Le, J Lesnock, J Lester, J Lubiński, J Menkiszak, B Ney, A Olawaiye, S Orsulic, A Osorio, L Robles-Díaz, M Ruebner, M Shah, R Sharma, YB Shvetsov, H Steed, A Talhouk, SE Taylor, N Traficante, RA Vierkant, C Wang, LR Wilkens, SJ Winham, J Benitez, A Berchuck, DD Bowtell, FJ Candido Dos Reis, LS Cook, A DeFazio, AOCs group, JA Doherty, PA Fasching, MJ García, EL Goode, MT Goodman, J Gronwald, DG Huntsman, BY Karlan, S Kommoss, F Modugno, JM Schildkraut, H-P Sinn, A Staebler, LE Kelemen, CE Ford, U Menon, PDP Pharoah, M Köbel, SJ Ramus
Journal:
Br J Cancer
Citation info:
128(1):137-147
Publication date:
1st Jan 2023
Full text
DOI